glp-1 for addiction treatment IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target GLP-1 drugs may help treat

Eligible patients receive individualized treatment recommendations based on their specific goals and clinical profile

Get your KLOW on Learn about our new peptide shot that helps you glow from the inside out

In an exploratory analysis of REWIND, the hazard of substantive cognitive impairment was reduced by 14% in the dulaglutide group [62]

Nov 1: Erosive GERD patients have a new treatment option after the FDA greenlit Phathom Pharmaceuticals Voquezna (vonoprazan) tabletswhich the gastrointestinal-focused company claims is the first major innovation to the U.S

Bispecific molecules are more often designed to target antigens expressed on the same cell or cells within the same environment but our data also demonstrates the feasibility of achieving dual pharmacology when targeting molecules in very different compartments: a soluble serum protein (PCSK9) and a GPCR predominately expressed in pancreatic -cells (GLP-1R)

Reversed-phase HPLC can resolve some misfolded species by their exposed surfaces, so the chromatographic method matters beyond the number it produces